There are multiple ways biopharmas create inclusive workplaces for LGBTQ+employees，and they go beyond employee resource groups and benefits。
6/3/2024
Johnson&Johnson announced data from the Phase3PERSEUS study showing deepening of responses and sustained minimal residual disease negativity at both10-5and10-6 levels with an induction regimen of DARZALEX FASPRO®in combination with bortezomib，lenalidomide and dexamethasone followed bya maintenance regimen of DARZAREX FASPRO®plus lenalidomide for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma。
6/3/2024
Johnson&Johnson announced new data from the Phase2PALOMA-2study evaluting subcutaneous amivantamab combined with lazertinib asafirst-line treatment in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon19 deletion or L858 mutations。
As evidenced by this week’s buyouts by J&J and Merck，Big Pharma appears to have found a sweet spot favoring smaller deals over megabillion-dollar acquisitions。
5/31/2024
Johnson&Johnson announced it has completed its acquisition of Shockwave Medical.Shockwave is now part of Johnson&Johnson and will operate as a business unit within Johnson&Johnson MedTech。
5/31/2024
Johnson&Johnson announced first data from the Phase3PALOMA-3study evaluting subcutaneous amivantamab combined with lazertinib in patients with locally advanced or metatic non-small cell lung cancer with epidermal growth factor receptor exon19 deletion or L858 mutations。
5/31/2024
Johnson&Johnson announced new data from the Phase3MARIPOSA study demonstrating the benefit of first-line treatment with RYBREVENT®in combination with lazertinib in patients with high-risk disease or clinical features，which occur in nearly85 percent of patients with non-small cell lung cancer with epidermal growth factor receptor mutations。
5/29/2024
Johnson&Johnson announced positive topline results from the pivotal Phase3MDD3001 clinical trial trial evaluating the efficy and safety of seltorexant asan adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms。
As AstraZeneca looks to climb toward the top of biopharma companies by revenue by the end of the decade，smaller companies are looking to join the ranks of the unofficial Big Pharma club。
Johnson&Johnson on on on Wednesday reported late-stage trial data showing its first-in-class orexin receptor antagonist reduced major depressive disorder symptoms asan adjunctive treatment in patients with insomnia。
5/28/2024
Johnson&Johnson（NYSE:JNJ）announced today it has entered into a definitive agreement with Numab Therapeutics to acquire from Numab's shareholders its wholly-owned subsidiary for the global rights to anovel，investigational first-in-class bispecific antibody，NM26，in an all-cash transaction of approximately$1.25billion。
5/28/2024
Numab Therapeutics AG announced that the Company has entered into a definitive agreement whereby Johnson&Johnson acquires Yellow Jersey Therapeutics，awholly-owned subsidiary of Numab to be spun-off to Numab's shareholders。
Johnson&Johnson’s deal for Numab Therapeutics’bispecific antibody NM26，slated to enter Phase II studies，comes on the heels of J&J’s$850 million Proteologix bispecific antibody acquisition。
Johnson&Johnson’s radiopharma candidate JNJ-6420 returned mixed results in an early-stage study，demonstrating strong strong biochemical and radiographic response but also resulting in four patient deaths。
Johnson&Johnson on on Tuesday released Phase III/III results showing its monoclonal antibody Tremfya is better than its blockbuster Stelara in terms of endoscopic outcomes in Crohn’s disease。
Despite weathering a difficult year，biopharma continues to see massive pay gaps between CEOs and their median employees，with top executives often earning hundreds of times more。
5/20/2024
Johnson&Johnson announced the first data from the Phase3QUASAR Maintenance Study that showed 50.0 percent of patients with moderately to severely active ulcerative colitis receiving subcutaneous TREMFYA®200mg every four weeks and 45.2 percent of patients receiving SC TREMFYA®100mg every eight weeks achieved the primary endpoint of clinical remission at Week44 compared to placebo。
5/16/2024
Acquisition advances Johnson&Johnson’sleading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis（AD）。
Johnson&Johnson announced Thursday it is paying$850 million in cash，plus a potential milestone payment，for privately held biotech Proteologix and its atopic dermatitis-focused bispecific antibody candidates。
The weight-loss drug bonanza continued in the first quarter of 2024 for Novo Nordisk and Eli Lilly，as Amgen also posted strong results，while Biogen and BMS struggled early in the financial year。
